What's Behind Regeneron's Stellar Q4 Update
Regeneron Pharmaceuticals (NASDAQ: REGN) is on a roll. Its shares jumped 29% last year. The biotech recently reported very promising results from a late-stage study of its COVID-19 antibody cocktail. The experimental therapy appears to be 100% effective at preventing symptomatic coronavirus infections.
And the roll continues. Regeneron reported its fourth-quarter and full-year 2020 results before the market opened on Friday. Here are the highlights from that update.
Image Source: Getty Images.
Source Fool.com
